Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureReza Ghalehtaki, Alireza Shariati, Zahra Moradi, Mohammad-Mahdi Aghaei, Romina Abyaneh
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Combination of immune checkpoint inhibitors and radiotherapy in locally advanced esophagogastric junction adenocarcinoma: A review
10.1002/cncr.35561 · 2024
Induction sintilimab and chemotherapy followed by concurrent chemoradiotherapy for locally advanced esophageal cancer: a proof-of-concept, single-arm, multicenter, phase 2 trial
10.1016/j.eclinm.2024.102471 · 2024
How to perform a meta-analysis with R: a practical tutorial
2019
Atezolizumab following definitive chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma – a multicenter phase 2 trial (EPOC1802)
10.1038/s43018-025-00918-1 · 2025
Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102
10.1200/jco.2005.04.7118 · 2007
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2024
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
10.1097/coc.0000000000000239 · 2016
Predictive role of ctDNA in esophageal squamous cell carcinoma receiving definitive chemoradiotherapy combined with toripalimab
10.1038/s41467-024-46307-7 · 2024
Tislelizumab Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized, Phase II Trial (EC-CRT-002)
10.1200/jco-25-03044 · 2026
Neoadjuvant chemotherapy may not benefit esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy
10.1016/j.jcma.2017.06.014 · 2017
Association Between Lymphopenia and Survival Outcomes in Esophageal Carcinoma Patients Receiving Combined Immunotherapy and Chemoradiotherapy
10.1093/oncolo/oyad094 · 2023
Mechanistic rationales for combining immunotherapy with radiotherapy
10.3389/fimmu.2023.1125905 · 2023
Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial
10.1016/s1470-2045(14)70028-2 · 2014
Patterns of recurrence following definitive chemoradiation for patients with proximal esophageal cancer
10.1016/j.ejso.2021.02.001 · 2021
Induction immunochemotherapy followed by radiotherapy for patients with unresectable locally advanced or metastatic esophageal cancer: A propensity score-matched analysis
10.1016/j.intimp.2023.110955 · 2023
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma
10.1056/nejmoa2111380 · 2022
Induction immunochemotherapy followed by concurrent chemoradiotherapy improves survival in unresectable esophageal cancer: a systematic review, meta-analysis, and network meta-analysis
2026
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus
10.1056/nejm199206113262403 · 1992
Immunotherapy combined with definitive chemoradiotherapy for locally advanced unresectable esophageal squamous cell carcinoma
10.3389/fimmu.2025.1646568 · 2025
Immune checkpoint inhibitors combined with concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma
2024
Conversion Surgery Following Immunochemotherapy in Initially Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma-A Real-World Multicenter Study (RICE-Retro)
2022
Randomized study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer (ARTDECO study)
10.1200/jco.20.03697 · 2021
Long-Term Toxicity After Definitive Chemoradiotherapy for Squamous Cell Carcinoma of the Thoracic Esophagus
10.1200/jco.2003.03.055 · 2003
Current landscape of targeted therapy in esophageal squamous cell carcinoma
10.1016/j.currproblcancer.2024.101152 · 2024
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
10.1016/s1470-2045(19)30626-6 · 2019
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
10.1056/nejmoa2032125 · 2021
Induction immunotherapy plus chemotherapy followed by definitive chemoradiation therapy in locally advanced esophageal squamous cell carcinoma: a propensity-score matched study
10.1007/s00262-024-03649-x · 2024
Efficacy of combined immunotherapy and predictive role of inflammatory markers in elderly ESCC patients
10.1080/20565623.2025.2564018 · 2025
INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy
10.1200/jco.2002.20.5.1167 · 2002
Neoadjuvant versus definitive chemoradiation in patients with squamous cell carcinoma of the esophagus
10.1186/s13014-019-1270-8 · 2019
Nivolumab with definitive chemoradiotherapy for oesophageal squamous cell carcinoma (NOBEL): a multicentre, single-arm, phase 2 feasibility trial
10.1016/j.eclinm.2025.103689 · 2026
Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
10.1016/j.annonc.2022.07.003 · 2022
Induction chemotherapy plus camrelizumab followed by concurrent chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma (ImpactCRT): A single-arm, phase Ⅱ trial
2023
Understanding the impact of radiation-induced lymphopenia: Preclinical and clinical research perspectives
2024
Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus
10.1200/jco.2005.00.034 · 2005
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
10.1016/s0140-6736(21)01234-4 · 2021
Clinical observation of anti-PD-1/PD-L1 immunotherapy plus concurrent chemoradiotherapy for locally advanced esophageal squamous cell carcinoma
10.1016/j.cyto.2025.157096 · 2026
ESMO–ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors
10.1016/j.annonc.2025.09.008 · 2026
Combining radiotherapy with immunotherapy: the past, the present and the future
10.1259/bjr.20170157 · 2017
The efficacy and safety of induction chemotherapy combined with sintilimab followed by concurrent chemoradiotherapy plus sintilimab sequencing maintaining with sintilimab for patients with unresectable locally advanced esophageal squamous cell carcinoma
10.1186/s12885-025-13457-w · 2025
Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trial
10.1016/s1470-2045(23)00060-8 · doi-reference
Dissecting esophageal squamous-cell carcinoma ecosystem by single-cell transcriptomic analysis
10.1038/s41467-021-25539-x · doi-reference
Iparomlimab and tuvonralimab (QL1706) combined definitive chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma (QL1706-IIT-02): a single arm, phase 2 trial
10.1016/j.eclinm.2026.103758 · doi-reference
Efficacy and safety of combined treatment with pembrolizumab in patients with locally advanced or metastatic esophageal squamous cell carcinoma in the real world
10.21037/atm-22-2779 · doi-reference
Radiotherapy: Brightness and darkness in the era of immunotherapy
10.1016/j.tranon.2022.101366 · doi-reference
Impact of consolidation immunotherapy after definitive chemoradiotherapy in locally advanced esophageal squamous cell carcinoma: a real-world multicenter study
10.1016/j.intimp.2025.115666 · doi-reference
High-dose versus standard-dose intensity-modulated radiotherapy with concurrent paclitaxel plus carboplatin for patients with thoracic esophageal squamous cell carcinoma: a randomized, multicenter, open-label, phase 3 superiority trial
10.1016/j.ijrobp.2022.11.006 · doi-reference
A narrative review of combining radiation and immunotherapy in gastroesophageal cancers
10.21037/tcr-20-2210 · doi-reference
Definitive chemoradiotherapy combined with anti-PD-1 immunotherapy for inoperable esophageal squamous cell carcinoma: a multicenter real-world study
10.1080/15384047.2025.2504726 · doi-reference
Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma: The NEOCRTEC5010 Randomized Clinical Trial
10.1001/jamasurg.2021.2373 · doi-reference
A phase III multicenter randomized clinical trial of 60 Gy versus 50 Gy radiation dose in concurrent chemoradiotherapy for inoperable esophageal squamous cell carcinoma
10.1158/1078-0432.ccr-21-3843 · doi-reference
Atezolizumab with or without tiragolumab in unresectable esophageal squamous cell carcinoma following definitive concurrent chemoradiotherapy (SKYSCRAPER-07): a randomised, phase III study
10.1016/j.annonc.2026.07.413 · doi-reference
Induction chemotherapy plus definitive chemoradiotherapy versus chemoradiotherapy alone in esophageal squamous cell carcinoma: Long-term results and exploratory analyses of a randomized controlled trial
10.1200/jco.2023.41.16_suppl.4061 · doi-reference
Immunotherapy and radiation therapy sequencing: State of the data on timing, efficacy, and safety
10.1002/cncr.33424 · doi-reference
Radiotherapy dose may not affect prognosis in ESCC patients receiving first-line chemoradiotherapy-immunotherapy: A multicenter retrospective study
10.1007/s00262-025-04261-3 · doi-reference
Impacts of neoadjuvant chemoradiotherapy on the immune landscape of esophageal squamous cell carcinoma
10.1016/j.ebiom.2022.104371 · doi-reference
Failure patterns in patients with esophageal cancer treated with definitive chemoradiation
10.1002/cncr.26586 · doi-reference
Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial
10.1158/1078-0432.ccr-24-1236 · doi-reference